New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis Data support frexalimab as a [...]
First data showing Ocrevus (ocrelizumab) treatment effect on disability progression in non-active secondary progressive multiple sclerosis [...]
Paris, France, March 10, 2020 – MedDay Pharmaceuticals announced today that the second pivotal Phase III trial (SPI2) of its [...]
A recent article by Kessler Foundation researchers demonstrated g people with multiple sclerosis (MS). The article, "Brain activation [...]
From VOA Learning English, this is the Health & Lifestyle report. An estimated two million people around the world have [...]
One of the highlights at the “Comprehensive Care in MS and Symptom Management” session of the Consortium of Multiple Sclerosis Centers [...]
Stem Cell Update Presented at MS Conference for Healthcare Professionals Cooperative Meeting of CMSC & ACTRIMS, May 28-31, 2014, [...]
